Check that the push button is pressed completely in and locked. Open the slide and make sure that Penfill® is inserted correctly. If Penfill® is damaged or empty, change it. Check that the slide is closed, and prime Innovo® until insulin appears at the needle tip.

No insulin appears when I prime Innovo® and the push button will not go in.

The needle may be blocked. Change the needle and prime Innovo® until insulin appears at the needle tip.

To open the slide, dial back to zero and press the push button completely in until it locks. Then change Penfill® as described on page 22.

WHAT DO I DO IF...?

Choosing the dose

I cannot release the push button. Make sure that the slide is closed completely. The release button is locked until the slide is closed.

I want to cancel or change the dialled dose.

Dial back to zero and press the push button completely in. Your last dose and the time passed since delivery will reappear on the display. You can increase, decrease or cancel the dialled dose until you press the push button.

Do not change the dose after you have pressed the push button.

25

Page 28 Page 30
Page 29
Image 29
Novo Nordisk 510620 manual What do I do IF...?
Page 28 Page 30

510620 specifications

Novo Nordisk 510620 is a cutting-edge medication developed by the renowned healthcare company Novo Nordisk, which specializes in diabetes care and other chronic diseases. As a part of Novo Nordisk's innovative product portfolio, 510620 is particularly aimed at addressing the needs of patients with type 2 diabetes, a condition that affects millions worldwide.

One of the main features of Novo Nordisk 510620 is its formulation as a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone that plays a crucial role in glucose metabolism. By mimicking the action of this hormone, 510620 stimulates insulin secretion in response to meals, inhibits glucagon release, and promotes satiety. This multi-faceted approach not only helps in lowering blood sugar levels but also aids in weight management, making it particularly suitable for overweight individuals with type 2 diabetes.

In terms of technology, Novo Nordisk 510620 utilizes a novel delivery system that enhances the bioavailability and stability of the active ingredient. This innovative technology involves an injectable formulation that is designed for easy administration, with pre-filled pens that allow patients to self-inject the medication comfortably. The convenience of the delivery system assists in improving patient adherence to treatment protocols, an essential factor in managing chronic conditions such as diabetes.

Another characteristic of Novo Nordisk 510620 is its cardiovascular benefits. Clinical studies have shown that patients using this medication not only achieve better glycemic control but also experience a reduction in the risk of major cardiovascular events. This attribute is critical, considering the high prevalence of cardiovascular complications associated with diabetes.

Safety and tolerability are also key aspects of Novo Nordisk 510620. The medication has undergone rigorous clinical trials, which have demonstrated a favorable safety profile, with common side effects being mild to moderate. Regular monitoring and education about potential side effects play a vital role in ensuring that patients can use 510620 effectively.

In summary, Novo Nordisk 510620 represents an advanced treatment option for type 2 diabetes, characterized by its GLP-1 receptor agonist activity, innovative delivery technology, cardiovascular benefits, and strong safety profile. By continually working on research and development, Novo Nordisk aims to improve the quality of life for individuals affected by chronic diseases, making substantial contributions to the field of diabetes management.
Top Page Image Contents